The combination of stroke and COVID-19 infection is often characterized by severe clinical symptoms, with a high incidence of complications and adverse outcomes in such patients. The key pathogenetic mechanism of stroke development in the context of COVID-19 is the hyperproduction of proinflammatory cytokines, which leads to disturbances in the hemostatic system, endothelial dysfunction, and, consequently, the formation of thrombotic complications. The risk of large cerebral vessel involvement in patients with stroke and COVID-19 is significantly higher than in patients without COVID-19, and during the first year after disease onset, the threat of recurrent vascular events persists. The development of post-COVID syndrome in this patient category is associated with the persistence of immune and metabolic disorders. Among the most common manifestations of post-COVID syndrome are cognitive impairment, reduced attention, fatigue, headaches, sleep disturbances, and anxiety-depressive states. The presence of comorbidities, particularly cardiovascular and metabolic diseases, exacerbates the course of post-COVID syndrome and worsens the prognosis. Early diagnosis of hemostatic disorders and monitoring of proinflammatory cytokines are of particular importance, as they enable timely therapeutic adjustments. A promising approach is the use of monoclonal antibodies targeting interleukin-6 receptors, which helps reduce the incidence of multiorgan complications. Comprehensive rehabilitation, including pharmacological, physical, respiratory, and psycho-emotional interventions, should be carried out individually, taking into account the severity of neurological deficits and comorbid conditions. Thus, patients who have suffered a stroke in the context of COVID-19 require a multi-level approach aimed at correcting post-COVID manifestations and preventing recurrent vascular events.